SOURCE: BioMedReports

BioMedReports

March 06, 2012 08:08 ET

Exact Sciences' Colorectal Cancer Test Could Have Big Impact, Says CEO

LOS ANGELES, CA--(Marketwire - Mar 6, 2012) - Exact Sciences Corporation (NASDAQ: EXAS), the molecular diagnostics company focused on colorectal cancer, has been steadily inching towards their commercialization goals and one need only look at their stock chart to see the steady, reliable advancement.

In fact, inch by inch, shares of the company have been progressively climbing since BioMedReports began covering it in early 2009.

Based in Madison, Wisconsin, Exact Sciences was incorporated in the mid-nineties, with a vision to develop a molecular diagnostic colorectal cancer screening test that detects both cancer and pre-cancer. Now, if things go as planned, Exact Sciences could be launching the Cologuard test within two years.

"Exact Sciences is a company that is totally focused on the early detection of colorectal cancer," explains Kevin T. Conroy who was named President and Chief Executive Officer of Exact Sciences in April 2009. "In the U.S. there are one hundred and forty thousand new cases of colon cancer every year and fifty thousand deaths. This is the cancer that is known as the most preventable cancer."

"We think a non-invasive test that is easy to use and patient friendly could have a big impact at being able to detect disease early," said Mr. Conroy.

Exact Sciences' non-invasive stool-based DNA (sDNA) test provides an additional tool for cancer screening that allows for early detection of the disease state. The company is engaged in developing an investigational device for the detection of both cancer and pre-cancers by combining methylation markers, mutation markers and a fecal immunochemical test (FIT).

In a video interview, Conroy explains the firm's plans in detail and shares his thoughts on how the test could have an impact on the entire field of colorectal cancer screening.

The video interview with Kevin T. Conroy is now available at:

http://www.biomedreports.com/2012030690725/exact-sciences-non-invasive-test-could-have-big-impact-says-ceo-conroy.html

In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions, which can be used to make more profitable trades during these volatile markets, can go to:

http://biomedreports.com/fdacal.html

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556